D-1 Gene Polymorphism in Salivary Gland Tumors
Journal of Dental School, Shahid Beheshti University of Medical Sciences,
Vol. 37 No. 1 (2019),
21 September 2019
Objectives This study aimed to assess PD-1gene polymorphism in salivary gland tumors in patients referred to Khalili Hospital in Shiraz.
Methods This case-control study evaluated 48 patients with salivary gland tumors and 100 age- and sex-matched healthy controls. First, 5cc blood samples were obtained from patients and transferred to vials containing anti-coagulated EDTA. DNA was extracted, and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed on the samples. The PD-1 gene genotype was determined using the Fermentas kit. After 24 hours of incubation, all the samples were electrophoresed. The genotypes were reported based on the size of bands, and the chi-square test was applied. To compare the alleles, the Fisher’s Exact test was applied. The Yates correction was used to compare the genotype and genotypic alleles based on the tumor grade.
Results The mean age was 44.81±15.69 years in patients and 46.54± 13.86 years in controls. Statistical analysis did not show any significant difference in PD1 gene polymorphism between the two groups (P=0.098). No significant correlation was found between the genotype frequency and lymph node involvement (P=0.06), tumor genotype (P=0.12), side (right or left) (P=0.22), tumor location (P=0.27), and size or invasion of the tumor to the surrounding tissue (P=0.14). PD1.3 genotype frequency did not differ significantly between malignant and benign tumors (P=0.6).
Conclusion This study did not reveal any significant difference in genotype frequency of PD1.3 in the patient and control groups; however, further studies are needed with a larger sample size to obtain more accurate results.
- Programmed Cell Death 1 Receptor
- Salivary Gland Neoplasms
How to Cite
Nanci A. Ten cate's oral histology-pageburst on vitalsource: development, structure, and function.Philadelphia: Elsevier Health Sciences. 2007; Chap 11: 290-318.
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov;29(32):4294-301.
Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010 May;74(2):134-48.
Bonfils P, Elouaret Y, Badoual C, Halimi P, Bigorgne C. Granular cell tumours (Abrikossoff's tumour) of the parotid region. Rev Laryngol Otol Rhinol (Bord). 2006;127(3):183-5.
Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R. Major and minor salivary glands tumours. Crit Rev Oncol Hematol. 2003 Feb;45(2):215-25.
Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013 Sep;12(11):1091-100.
Ansari MH. Salivary gland tumors in an Iranian population: a retrospective study of 130 cases. J Oral Maxillofac Surg. 2007 Nov;65(11):2187-94.
Shishegar M, Ashraf MJ, Azarpira N, Khademi B, Hashemi B, Ashrafi A. Salivary gland tumors in maxillofacial region: a retrospective study of 130 cases in a southern Iranian population. Patholog Res Int. 2011;2011:934350.
Schapher M, Wendler O, Gröschl M. Salivary cytokines in cell proliferation and cancer. Clin Chim Acta. 2011 Sep 18;412(19-20):1740-8.
Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H. Activation of innate immune responses through Toll‐like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med. 2009 Jan;38(1):42-7.
Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. J Rheumatol. 2005 Nov;32(11):2156-63.
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004 Aug;10(15):5094-100.
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012 Apr;24(2):207-12.
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007 Apr;13(7):2151-7.
Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009 Oct;15(20):6341-7.
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005 Apr;11(8):2947-53.
Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003 Oct;63(19):6501-5.
Riley JL. PD‐1 signaling in primary T cells. Immunol Rev. 2009 May;229(1):114-25.
Mojtahedi Z, Mohmedi M, Rahimifar S, Erfani N, Hosseini SV, Ghaderi A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene. 2012 Oct;508(2):229-32.
Haghshenas MR, Naeimi S, Talei A, Ghaderi A, Erfani N. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep. 2011 Aug;38(6):4205-10.
Ghaderi A. CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iranian Iran J Immunol. 2011 Sep;8(3):127-49.
Dehaghani AS, Kashef MA, Ghaemenia M, Sarraf Z, Khaghanzadeh N, Fattahi MJ, et al. PDCD1, CTLA-4 and p53 gene polymorphism and susceptibility to gestational trophoblastic diseases. J Reprod Med. 2009 Jan;54(1):25-31.
Lin S, Yen J, Tsai J, Tsai W, Ou T, Liu H, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 2004 50(3):770-5.
Savabkar S, Azimzadeh P, Chaleshi V, Mojarad EN, Aghdaei HA. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. Gastroenterol Hepatol Bed Bench. 2013 Fall;6(4):178-82.
Bolstad AI, Eiken HG, Rosenlund B, Alarcón‐Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte–associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum. 2003 Jan;48(1):174-85.
- Abstract Viewed: 231 times
- PDF Downloaded: 106 times